Novavax(NVAX) - 2024 Q3 - Quarterly Results

Press Release Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights • U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates • Achieved total revenue of $85 million in the third quarter of 2024 • Ended the third quarter of 2024 with $1 billion in cash and receivables • Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individua ...